Direkt zum Inhalt
Merck
  • In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus.

In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus.

Molecular therapy : the journal of the American Society of Gene Therapy (2019-04-10)
Rianne N Esquivel, Ami Patel, Sagar B Kudchodkar, Daniel H Park, Karin Stettler, Martina Beltramello, Jeffrey W Allen, Janess Mendoza, Stephanie Ramos, Hyeree Choi, Piyush Borole, Kanika Asija, Mamadou Bah, Shareef Shaheen, Jing Chen, Jian Yan, Amy C Durham, Trevor R F Smith, Kate Broderick, Ghiabe Guibinga, Kar Muthumani, Davide Corti, Laurent Humeau, David B Weiner
ZUSAMMENFASSUNG

Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs), which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody, supporting the importance of this new platform.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Millipore
Immobilon®-FL PVDF-Transfermembran, 0.45 μm pore size, 7 X 8.4 cm sheets
Sigma-Aldrich
Anti-Human IgG (H+L)-Peroxidase antibody produced in donkey, affinity isolated antibody, lyophilized powder